Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline
- Written by PR Newswire Asia - Daily Bulletin Au RSS
![]() |
Interim analysis planned for January 2026 with final trial results in late 2026
Highlights:
- With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed for January 2026 and the timeline for final results reconfirmed for late 2026
- An independent Data Monitoring Committee will review all...